Fatty Liver Disease & Liver Cirrhosis Study: Clinical, Metabolic, and Outcomes

Fatty Liver Disease, encompassing both Alcoholic Fatty Liver Disease (AFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD), has emerged as a major global health concern. AFLD is directly linked to excessive alcohol consumption, whereas NAFLD is associated with metabolic disorders such as obesity, diabetes, and dyslipidemia. Both conditions can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) if left unmanaged. Cirrhosis, the end-stage of chronic liver disease, contributes significantly to global morbidity and mortality.

The study behind the AFLD dataset aims to explore the long-term health outcomes of individuals diagnosed with fatty liver disease compared to a matched control group. Specifically, the study follows subjects forward to evaluate metabolic conditions, cardiovascular outcomes, and mortality rates. By analyzing this dataset, researchers can identify key risk factors for disease progression and mortality, allowing for better prevention and intervention strategies. Study Design and Data Description

The dataset consists of 18,012 individuals, categorized into two primary groups:
1. AFLD Cases: Individuals diagnosed with Alcoholic Fatty Liver Disease.
2. Matched Controls: Individuals without AFLD, but matched on factors such as age, gender, and BMI.

By selecting a control group with similar demographics, the study aims to isolate the effects of AFLD on long-term health outcomes. The inclusion criteria for AFLD cases likely involve diagnostic confirmation via imaging, liver function tests, and clinical assessment. Control subjects were chosen to ensure comparability, minimizing confounding effects.

Data Collection Methodology
The dataset represents a longitudinal cohort study, meaning subjects were tracked over time to observe health outcomes. Follow-up data include:
• Time to death (futime) or last known contact.
• Mortality status (status), where 0 = alive at last follow-up and 1 = deceased.

This method allows to investigate the progression of AFLD, the development of metabolic complications, and survival trends.

Dataset Variables and Importance
The AFLD dataset includes 10 key variables, each providing valuable insights:
1. id: A unique identifier for each subject.
2. age: Age at study entry, a crucial factor influencing metabolic and liver health.
3. male: A binary variable (0 = female, 1 = male), allowing gender-based comparisons.
4. weight (kg): A key metabolic marker, though missing for some participants.
5. height (cm): Helps in calculating BMI.
6. bmi (Body Mass Index): Derived from weight and height, it is a major risk factor for metabolic and liver diseases.
7. case.id: The matched AFLD case ID for each control.
8. futime: Follow-up duration in days, essential for survival analysis.
9. status: Survival outcome, distinguishing between deceased and surviving subjects.

Each variable plays a crucial role in understanding disease progression, mortality risks, and comorbid conditions.